Thyrotropinoma When Surgical Adenomectomy Did Not Achieve Full Remission
Clinical Scenario
Thyrotropinoma is a TSH-secreting pituitary adenoma. When surgical removal of the adenoma does not deliver complete biochemical and clinical remission, a structured next-line medical protocol is applied to restore hormonal control and address the residual tumour.
Prior Treatment — Goals Not Met
First-line management is surgical adenomectomy (transsphenoidal or subfrontal approach). Escalation to medical therapy is triggered when the expected post-surgical endpoints are not reached: undetectable TSH one week after surgery, clinical remission of hyperthyroidism, resolution of neurological symptoms, and normalisation of circulating thyroid hormones and TSH.
Next-Line Medical Approach (Partial Overview)
Medical therapy for persistent or incompletely resected thyrotropinoma is built around a class of agents demonstrated to suppress TSH secretion from neoplastic thyrotropes. In certain biochemical responses, an additional substitution strategy may be required. An alternative receptor-targeted pharmacological class is also available in this setting.
Full agent selection, sequencing, and monitoring criteria available in the structured protocol →
Treatment Goals
- Restoration of the euthyroid state with normalisation of circulating thyroid hormone levels
- Reduction of TSH secretion
- Reduction in goiter size
- Pituitary tumour mass shrinkage
- Improvement of vision
References
DOI: 10.1159/000351007
- Medical treatment of TSHomas is mainly based on the administration of somatostatin analogs that have been demonstrated to be highly effective in reducing TSH secretion from neoplastic thyrotropes.
- Treatment with long-acting somatostatin analogs, such as octreotide LAR® or lanreotide SR® or lanreotide Autogel®, induces a reduction in TSH and α-GSU secretion in almost all cases, with restoration of the euthyroid state in the majority of them.
- The marked somatostatin-induced suppression of TSH secretion and consequent biochemical hypothyroidism seen in some patients may require L-T4 substitution.
- Dopamine type 2 receptors are present in most TSHomas and thus dopamine agonists, such as bromocriptine or cabergoline, have been used in the treatment of affected patients.
- Circulating thyroid hormone levels normalized in more than 90% of patients and goiter size is significantly reduced by somatostatin analog therapy in about 30% of cases.
- Somatostatin analog treatment induces a significant tumor mass shrinkage in about 40% of patients and vision improvement in about 70% of them.
View source ↗